Skip to main content

Table 4 Effect of each parameter on OS according to baseline values and to the variation between T1 value (after 1 month of therapy) and T0 value (baseline value). This difference has been indicated as delta value (Δ)

From: Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Parameter Univariate Two-variable Multivariablea
Variable Timepoint Value p HR Lower HR Upper HR p HR Lower HR Upper HR p HR Lower HR Upper HR
Platelets Basal  + 10,000      0.041 1.020 1.001 1.039
Δ Ref ≤ 25,000      0.022 1.512 1.063 2.151
White blood cell count Basal  + 100       < 0.001 1.009 1.005 1.013
Δ Ref ≤ 1920       < 0.001 3.246 2.171 4.854  < 0.001 2.918 1.882 4.526
Neutrophils Basal  + 100       < 0.001 1.014 1.010 1.018  < 0.001 1.011 1.005 1.016
Δ Ref ≤ 310       < 0.001 1.880 1.330 2.659
Lymphocytes Basal  + 100      0.045 0.977 0.955 0.999
Δ Ref ≥ -300       < 0.001 2.319 1.578 3.409 0.038 1.627 1.028 2.576
NL ratio Basal  + 1       < 0.001 1.279 1.169 1.400
Δ Ref ≤ 0.86       < 0.001 2.908 2.012 4.202
PL ratio Basal  + 1      0.006 1.003 1.001 1.005 0.022 1.003 1.000 1.005
Δ Ref ≤ 22.85       < 0.001 2.019 1.429 2.853 0.140 1.378 0.901 2.109
Age Basal  + 1 0.255 1.008 0.994 1.021     
Sex Basal Ref F 0.282 0.829 0.589 1.166     
Number of metastatic sites Basal Ref ≥ 3 0.089 0.746 0.532 1.046     
LDH Basal Ref elevated  < 0.001 0.395 0.276 0.564       < 0.001 0.499 0.344 0.724
  1. Statistically significant values in bold
  2. At the Δ timepoint the variables have been dichotomized and the “value” represents the reference category
  3. HR (hazard ratio) values are expressed in terms of risk of mortality
  4. aAfter stepwise selection